Stem cells and diabetes: how Cheongdam Cell Clinic frames it

On its 淸(Rejuvenation)CELL programme page, Cheongdam Cell Clinic lists diabetes among the age-related conditions where intravenous stem-cell injection has, in the clinic's own marketing wording, been 'proven to prevent and treat'. This article reports how the clinic communicates that claim; it does not endorse the scientific accuracy of the wording itself.

Type 2 diabetes largely involves insulin resistance and declining pancreatic beta-cell function. A concept often cited in the broader stem-cell field is tissue-regeneration and anti-inflammatory potential, which could relate indirectly to insulin resistance — but there is no clear consensus that uncultured, intravenously injected bone-marrow stem cells directly affect blood-sugar control.

Internationally recognised diabetes treatment remains oral or injectable glucose-lowering medication, insulin in some cases, plus consistent diet control and exercise. Periodic HbA1c monitoring remains necessary for all diabetic patients regardless of whatever supplementary programme they may also pursue.

Cheongdam Cell Clinic explains that the 淸(Rejuvenation)CELL programme harvests the patient's own bone marrow, isolates cells without a culture step, then reinjects them intravenously within half a day. The clinic's emphasis is on convenience and the autologous nature of the cells, which reduces rejection risk compared with donor-derived cells.

Diabetic patients considering this programme should disclose their diabetes type, recent HbA1c levels, complications such as diabetic kidney or eye disease, and current medications to the clinic's doctors before deciding, since poorly controlled blood sugar can also affect wound healing after the bone-marrow harvesting step.

Readers should be careful not to over-interpret the clinic's phrase 'prevent and treat' too literally, since no publicly cited research accompanies it. Prospective patients should ask the clinic directly whether it has follow-up data on diabetic patients who took this programme, and should seek a second opinion from an endocrinologist in Thailand before deciding.

This type of supplementary programme is better viewed as part of holistic care for people who already manage their diabetes well and want additional vascular support, rather than as a first-line option for uncontrolled diabetes. Setting realistic expectations helps patients make safer decisions.

Before travelling to Seoul for the programme, patients should bring recent blood test results, a medication list and complication history for the clinic to assess, and request cost details in writing, since the clinic does not publish prices publicly.